Piramal Pharma Ltd. updates KMP contact details for SEBI disclosures
Piramal Pharma Limited has updated the contact details for its Key Managerial Personnel (KMP) as per SEBI regulations. Mr. Vivek Valsaraj (CFO) and Ms. Pratibha Mishra (Interim Company Secretary) are designated for materiality assessments and disclosures to stock exchanges.
This is a routine compliance update and does not involve any significant operational, financial, or strategic changes that would materially impact the company's stock performance or business.
The announcement is a routine regulatory update regarding contact details of KMPs and does not contain any specific financial or operational information that would impact the company's sentiment.
Piramal Pharma Limited (PPL) has provided updated contact details for its Key Managerial Personnel (KMP) in compliance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These details are for determining the materiality of events or information and for making necessary disclosures to the stock exchanges.
The updated contact information includes Mr. Vivek Valsaraj, Chief Financial Officer, with the email ID vivek.valsaraj@piramal.com, and Ms. Pratibha Mishra, Interim Company Secretary, with the email ID pratibha.mishra@piramal.com. These individuals will be responsible for handling disclosures and materiality assessments as per SEBI regulations.
The company has registered its office in Mumbai, India, and its shares are listed on both BSE Limited (scrip code: 543635) and the National Stock Exchange of India Limited (symbol: PPLPHARMA). This announcement serves as a formal record of these updated KMP contact details.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.